The numbers were pristine. Revenue of $2.89 billion, an 18.5% jump. Adjusted earnings per share of $2.80, handily beating the $2.50 consensus. Yet when Intuitive Surgical reported its second-quarter results on July 16, the stock cratered more than 9% in after-hours trading. The disconnect between operational performance and market reaction has rarely been so stark — and the company is now scrambling to redirect the narrative with a sweeping artificial intelligence strategy.
The culprit wasn’t a miss. It was a guidance that stayed put. Management reaffirmed its 2026 forecast for global da Vinci procedure growth of 13.5% to 15.5%, adding that the outcome would likely land in the middle of that range. For a stock that had commanded a premium valuation built on acceleration, a simple confirmation felt like a letdown. The shares have since shed 39.42% year-to-date, touching a 52-week low of €289.05 on July 23 before recovering slightly to close Friday at €296.35, up 1.58% on the session.
The AI Pivot: Five Layers of Surgical Intelligence
Just days after the selloff, Intuitive Surgical used the Society of Robotic Surgery conference to unveil a five-tiered artificial intelligence framework designed to reframe its long-term growth story. The architecture starts with standardized operating room data and culminates in what the company calls “supervised autonomy” — AI assistance that expands surgeon capabilities while keeping ultimate control in human hands.
Iman Jeddi, senior vice president and general manager of the da Vinci platforms, described the initiative as a “capabilities stack” covering the entire surgical journey: before, during, and after procedures. Each layer builds on the one below it. The foundation is a data moat that competitors will struggle to replicate: more than 20 million procedures have been performed globally using da Vinci systems, creating an unmatched repository of surgical video and clinical decision-making logic.
Researchers also presented a novel AI framework that learns from surgical videos, capturing not just visual patterns but the reasoning behind clinical choices — risk assessment, next-step planning, and intraoperative judgment. It’s a bet that data, not hardware alone, will define the next era of robotic surgery.
The Bear Case: Structural Headwinds, Not Just Sentiment
The AI push arrives as the bull case faces its most serious challenge in years. The most immediate pressure point is the U.S. market, where procedure growth slowed to 12% year-over-year — particularly in “benign” surgical cases that patients are increasingly postponing for economic reasons.
The company itself identifies the culprit: the expiration of enhanced tax credits under the Affordable Care Act, which has stripped insurance coverage from many Americans. CFO Jamie Samath described the impact as a “moderate negative effect” on procedure volumes. The warning from hospital operator HCA Healthcare, which had flagged declining demand for surgical procedures after pandemic-era subsidies lapsed, only reinforced the concern.
International markets add another layer of complexity. Chinese competitors in robotic surgery are gaining ground, while shifting procurement policies in the region are dampening demand. Lower government tendering activity is making it harder to place high-margin systems in Asia-Pacific.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Several major brokers have cut their price targets — Bernstein from $750 to $685, Stifel from $670 to $550 — while maintaining their ratings. Citi removed Intuitive Surgical from its list of near-term catalysts. Bernstein warned that U.S. growth concerns “will spark debates and weigh on the stock, especially heading into the third quarter.” With a 30-day annualized volatility of 54.60%, the stock trades well below its 50-day moving average of €353.95 and its 200-day average of €417.70 — a technical setup that could attract further sellers on any disappointment.
The Bull Case: Fundamentals Running Away From the Stock
For optimists, the selloff has created a rare entry point. The company’s operating metrics continue to improve even as the stock price deteriorates. Revenue accelerated 19% in the latest quarter, driven by more procedures, higher leasing income, and a growing installed base.
The da Vinci 5, the newest system generation, is showing early promise. First data indicates roughly 11% higher clinical utilization compared with the previous Xi platform. System placements are accelerating: 468 new da Vinci systems in the second quarter, up from 395 a year earlier, with 246 of those being da Vinci 5 units versus 180 previously. The installed base reached 11,710 systems as of June 30, up 12% year-over-year.
Profitability is also improving. The company raised its 2026 adjusted gross margin guidance to 68%–69%, from 67.5%–68.5%, citing the removal of tariff pressure, a tariff refund, and lower product costs.
Analyst reactions, despite the lowered price targets, remain predominantly constructive. Bernstein retains its “Outperform” rating, the most bullish among major houses. Stifel reaffirmed its buy recommendation after surveying 100 robotic surgeons who still see Intuitive as the clear technology leader despite emerging competition. The consensus price target stands at €431.15, implying roughly 45.5% upside from Friday’s close. The relative strength index of 31.9 signals an oversold condition.
The Decisive Quarter Ahead
The next scheduled catalyst is the third-quarter earnings report, expected in the fourth quarter of 2026. Until then, the stock will oscillate between two competing narratives: a growing, margin-rich installed base versus mounting demand pressure from insurance losses, tougher year-over-year comparisons, and competitive inroads in China.
If procedure growth holds near the confirmed 13.5%–15.5% range and margins continue to improve, the case for a technical rebound toward the consensus target remains intact. But if U.S. procedure data in the third quarter confirms the slowdown tied to insurance losses and difficult comps, the July 23 low may prove temporary rather than foundational.
The AI strategy gives investors a long-term story to weigh against the near-term headwinds. Whether that story gains traction depends on one thing: whether the procedure growth rate in the second half of 2026 lands above or below the midpoint of management’s guidance. That single data point will determine whether the current rout was a valuation correction or the beginning of a more fundamental reassessment of Intuitive Surgical’s growth premium.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from July 26 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 26.
Intuitive Surgical: Buy or sell? Read more here...
